- Home
- CCIF vs IVVD Comparison
CCIF vs IVVD Comparison
Compare CCIF & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- IVVD
- Stock Information
- Founded
- CCIF 2011
- IVVD 2020
- Country
- CCIF United States
- IVVD United States
- Employees
- CCIF N/A
- IVVD N/A
- Industry
- CCIF Finance/Investors Services
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- CCIF Finance
- IVVD Health Care
- Exchange
- CCIF Nasdaq
- IVVD Nasdaq
- Market Cap
- CCIF 130.8M
- IVVD 123.8M
- IPO Year
- CCIF N/A
- IVVD 2021
- Fundamental
- Price
- CCIF $6.73
- IVVD $0.51
- Analyst Decision
- CCIF
- IVVD Strong Buy
- Analyst Count
- CCIF 0
- IVVD 3
- Target Price
- CCIF N/A
- IVVD $7.52
- AVG Volume (30 Days)
- CCIF 76.9K
- IVVD 1.7M
- Earning Date
- CCIF 01-01-0001
- IVVD 05-08-2025
- Dividend Yield
- CCIF 25.90%
- IVVD N/A
- EPS Growth
- CCIF N/A
- IVVD N/A
- EPS
- CCIF N/A
- IVVD N/A
- Revenue
- CCIF N/A
- IVVD $25,384,000.00
- Revenue This Year
- CCIF N/A
- IVVD $606.63
- Revenue Next Year
- CCIF N/A
- IVVD $83.30
- P/E Ratio
- CCIF N/A
- IVVD N/A
- Revenue Growth
- CCIF N/A
- IVVD N/A
- 52 Week Low
- CCIF $7.43
- IVVD $0.36
- 52 Week High
- CCIF $10.16
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- CCIF 39.74
- IVVD 38.07
- Support Level
- CCIF $6.27
- IVVD $0.46
- Resistance Level
- CCIF $7.10
- IVVD $0.56
- Average True Range (ATR)
- CCIF 0.36
- IVVD 0.06
- MACD
- CCIF 0.03
- IVVD 0.01
- Stochastic Oscillator
- CCIF 66.10
- IVVD 29.24
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.